Trial Profile
An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Sodium benzoate (Primary) ; Clozapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors SyneuRx International (Taiwan) corp
- 10 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2026.
- 10 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Sep 2026.
- 06 Apr 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.